Shrestha Priyadarsini1, Akhee Sarker-Nag1, Jeremy Allegood2,3,4,5, Charles Chalfant2,3,4,5, Dimitrios Karamichos1,6. 1. a Department of Ophthalmology , Dean McGee Eye Institute, University of Oklahoma Health Sciences Center , Oklahoma City , OK , USA . 2. b Hunter Holmes McGuire Veterans Administration Medical Center , Richmond , VA , USA . 3. c Department of Biochemistry and Molecular Biology , School of Medicine, Virginia Commonwealth University , Richmond , VA , USA . 4. d The VCU Johnson Center , Richmond , VA , USA . 5. e The VCU Massey Cancer Center , Richmond , VA , USA and. 6. f Department of Cell Biology , University of Oklahoma Health Sciences Center , Oklahoma City , OK , USA.
Abstract
PURPOSE: Diabetes mellitus (DM) is characterized by high blood sugar levels over a prolonged period. Long term complications include but not limited heart disease, stroke, kidney failure, and ocular damage. An estimated 382 million people are diagnosed with Type 2 DM accounting for 90% of the cases. Common corneal dysfunctions associated with DM result in impaired vision due to decreased wound healing, corneal edema, and altered epithelial basement membrane. Lipids play a fundamental role in tissue metabolism and disease states. We attempt to determine the role of sphingolipids (SPL) in human Type I and Type II diabetic corneas. MATERIALS AND METHODS: Cadaver corneas from healthy (non-diabetic/no ocular trauma), Type I (T1DM), and Type II diabetic (T2DM) donors were obtained and processed for lipidomics using LC-MS/MS. RESULTS: Our data show significant differences in the SPL composition between control, T1DM and T2DM corneas. Both T1DM and T2DM showed a 10-folddownregulation of sphingomyelin(SM), 5-fold up regulation of Ceramides (Cer) and 2-fold upregulation of monohexosylceramides (MHC). Differences were also seen in total amounts of SPL where Cer was increased by approximately 3 fold in both T1DM and T2DM where SM decreased by 50% in both T1DM and T2DM when compared to healthy controls. No differences were seen in MHC amounts. CONCLUSIONS: Overall, our data indicate major differences in SPL distribution in human diabetic corneas. Information on the sphingolipids role in cornea, corneal cell physiology, and diseases are very limitedwhich highlights the importance of these findings.
PURPOSE:Diabetes mellitus (DM) is characterized by high blood sugar levels over a prolonged period. Long term complications include but not limited heart disease, stroke, kidney failure, and ocular damage. An estimated 382 million people are diagnosed with Type 2 DM accounting for 90% of the cases. Common corneal dysfunctions associated with DM result in impaired vision due to decreased wound healing, corneal edema, and altered epithelial basement membrane. Lipids play a fundamental role in tissue metabolism and disease states. We attempt to determine the role of sphingolipids (SPL) in human Type I and Type II diabetic corneas. MATERIALS AND METHODS: Cadaver corneas from healthy (non-diabetic/no ocular trauma), Type I (T1DM), and Type II diabetic (T2DM) donors were obtained and processed for lipidomics using LC-MS/MS. RESULTS: Our data show significant differences in the SPL composition between control, T1DM and T2DM corneas. Both T1DM and T2DM showed a 10-folddownregulation of sphingomyelin(SM), 5-fold up regulation of Ceramides (Cer) and 2-fold upregulation of monohexosylceramides (MHC). Differences were also seen in total amounts of SPL where Cer was increased by approximately 3 fold in both T1DM and T2DM where SM decreased by 50% in both T1DM and T2DM when compared to healthy controls. No differences were seen in MHC amounts. CONCLUSIONS: Overall, our data indicate major differences in SPL distribution in humandiabetic corneas. Information on the sphingolipids role in cornea, corneal cell physiology, and diseases are very limitedwhich highlights the importance of these findings.
Authors: Christopher G Owen; Richard S B Newsom; Alicja R Rudnicka; Tim J Ellis; E Geoffrey Woodward Journal: Ophthalmology Date: 2005-10 Impact factor: 12.079
Authors: A Haimovitz-Friedman; C C Kan; D Ehleiter; R S Persaud; M McLoughlin; Z Fuks; R N Kolesnick Journal: J Exp Med Date: 1994-08-01 Impact factor: 14.307
Authors: Shrestha Priyadarsini; Tina B McKay; Akhee Sarker-Nag; Jeremy Allegood; Charles Chalfant; Jian-Xing Ma; Dimitrios Karamichos Journal: Exp Eye Res Date: 2016-10-11 Impact factor: 3.467
Authors: Hui Qi; Shrestha Priyadarsini; Sarah E Nicholas; Akhee Sarker-Nag; Jeremy Allegood; Charles E Chalfant; Nawajes A Mandal; Dimitrios Karamichos Journal: J Lipid Res Date: 2017-02-10 Impact factor: 5.922
Authors: Lynda A Wilmott; Richard C Grambergs; Jeremy C Allegood; Timothy J Lyons; Nawajes Mandal Journal: J Diabetes Complications Date: 2018-12-14 Impact factor: 2.852